We are live on ! Find out more
AVAI

Atlas Venture Associates IX Portfolio holdings

AUM $11.8M
1-Year Est. Return 58.35%
This Fund
S&P 500
This Quarter Est. Return
-20.2%
1 Year Est. Return
-58.35%
3 Year Est. Return
-89.8%
5 Year Est. Return
-87.69%
10 Year Est. Return
AUM
$60.8M
AUM Growth
-$32.8M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
7
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 88.34%
2 Technology 7.75%
3 Communication Services 3.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NTLA icon
1
Intellia Therapeutics
NTLA
$1.5B
$21.6M 35.49%
1,615,321
SPRO icon
2
Spero Therapeutics
SPRO
$68.3M
$14.6M 24.02%
1,376,968
SURF
3
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$6.6M 10.86%
4,645,453
SYBX
4
DELISTED
Synlogic
SYBX
$6.07M 10%
176,798
COGT icon
5
Cogent Biosciences
COGT
$6.69B
$4.84M 7.97%
840,384
CBLK
6
DELISTED
Carbon Black, Inc. Common Stock
CBLK
$4.71M 7.75%
181,273
SNAP icon
7
Snap
SNAP
$8.41B
$2.37M 3.91%
150,160

Similar funds

Atlas Venture Associates IX's Q3 2019 Portfolio in Review

As of Q3 2019, Atlas Venture Associates IX held 7 positions worth $60.8M, down 35% from $93.5M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q3 2019: portfolio turnover was 0%. Atlas Venture Associates IX opened no new positions and made no exits, leaving the 7-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 94% a quarter earlier, followed by Technology and Communication Services.

  • Atlas Venture Associates IX's ten largest holdings make up 100% of its $60.8M portfolio in Q3 2019.
  • Atlas Venture Associates IX opened 0 new positions and closed 0 in Q3 2019.
  • Atlas Venture Associates IX's portfolio value fell 35% quarter-over-quarter to $60.8M.

Based on Atlas Venture Associates IX's 13F filing for Q3 2019, filed 12 Nov 2019.